Effects of neuraminidase on O2 consumption and release of O2 and H2O2 from phagocytosing human polymorphonuclear leukocytes.
Neuraminidase type X (NMD-type-X, Sigma Chemical Co., St. Louis, Mo.), which is obtained from a further purification of neuraminidase type V (NMD-type-V, Sigma), markedly enhanced the release of O2- and H2O2 from phagocytosing human polymorphonuclear leukocytes (PMN). In contrast, O2 consumption by NMD-type-X-treated PMN was identical to that of untreated PMN. Morphological observations suggested that the enhancement of O2- and H2O2 release was caused by excessive release of the oxygen metabolites into the extracellular medium from incompletely formed phagocytic vacuoles as was observed with cytochalasin-B-treated cells. Our observations are in contrast to the previous reports of Tsan et al. that showed complete inhibition of both O2- and H2O2 release from phagocytosing PMN by the treatment with NMD-type-V.
D002474:Cell-Free System / Q000032:analysis; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism*; D009439:Neuraminidase / Q000494:pharmacology*; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects*; D010587:Phagocytosis; D012794:Sialic Acids / Q000494:pharmacology
D012794:Sialic Acids; D006861:Hydrogen Peroxide; D009439:Neuraminidase